Evaxion receives FDA fast-track designation for personalized cancer immunotherapy
COPENHAGEN, Denmark, Jan. 19, 2023 (GLOBE NEWSWIRE) — Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or…
Year: 2023
Salarius Pharmaceuticals to Present SP-3164 Targeted Protein Degrader Preclinical Data at the Inaugural Molecular Glue Drug Development Summit
Dr. Aundrietta Duncan to discuss mechanism of action and SP-3164 activity in cancer models Company…
Longeveron Announces Publication of Final Data from ELPIS I Trial of Lomecel-BTM for Hypoplastic Left Heart Syndrome in Peer-Reviewed Journal
— Full results published in European Heart Journal Open — — Study met primary safety…
Neuronetics and Greenbrook TMS Announce Six Year Exclusive Partnership
MALVERN, Pa. and TORONTO, Jan. 19, 2023 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a…
Dyadic Announces Sale of Equity Interest in Alphazyme
JUPITER, Fla., Jan. 19, 2023 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, or the “Company”)…
SELLAS Life Sciences to Host Key Opinion Leader Webinar on Galinpepimut-S Acute Myeloid Leukemia Program
Event will Feature Presentation from Hematology Oncology Expert Omer Jamy, MD, Phase 3 REGAL Study…
Viracta Therapeutics Announces Orphan Drug Designation Granted by the European Commission to Nana-val for the Treatment of Diffuse Large B-cell Lymphoma
Sixth orphan drug designation for Nana-val globally; second granted by the European Commission SAN DIEGO,…
BioCorRx Announces Completion of Treatment Phase of Study Subjects and Preliminary Safety Data from Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
ANAHEIM, CA, Jan. 19, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – BioCorRx Inc. (OTCQB: BICX)…
ABVC BioPharma ABV-1505 ADHD Phase IIa Results Presented at 2023 APSARD Conference
FREMONT, CA, Jan. 19, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ:…
MedAvail announces Strategic Restructuring of Business to Focus on Profitability
Company focusing on innovative technology and exit of pharmacy services Restructuring to further extend capital…
Outlook Therapeutics® Strengthens Medical Affairs and Commercial Expertise with Appointments of Surendra Sharma, MD, Senior Vice President of Medical Affairs and Glen Olsheim, Executive Director of Commercial Excellence
Dr. Sharma and Mr. Olsheim bring more than 30 years of combined experience in the…
Freeline Publishes Preclinical Proof-of-Concept Data for FLT190, its AAV Gene Therapy Candidate for Fabry Disease, in the Nature Journal Gene Therapy
Data show increased enzyme activity and reduction of harmful substrate, an established biomarker of efficacy…
Nautilus Biotechnology Partners with the Translational Genomics Research Institute (TGen) to Investigate Applications of Single-Molecule Proteomic Analysis in Diffuse Intrinsic Pontine Glioma (DIPG)
Collaboration enables TGen to gain access to data generated on prototype versions of Nautilus’ next-generation…
SOTIO Doses First Patient in AURELIO-05 Phase 2 Trial of Nanrilkefusp Alfa in Combination with Cetuximab
BASEL, Jan. 19, 2023 (GLOBE NEWSWIRE) — SOTIO Biotech, a clinical stage immuno-oncology company owned…
Vor Bio to Present Clinical Data from First Patient Treated with Trem-cel at 2023 Tandem Meetings
CAMBRIDGE, Mass., Jan. 19, 2023 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage cell…
Araris Biotech AG to Present at the 22nd Annual PepTalk: Protein Science and Production Week
ZURICH, Switzerland, Jan. 19, 2023 (GLOBE NEWSWIRE) — Araris Biotech AG, a company pioneering a…
Aprea Therapeutics to Participate in 6th Annual DNA Damage and Response (DDR) Inhibitors Summit
DOYLESTOWN, Pa., Jan. 19, 2023 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company…
aTyr Pharma Gains E.U. Patent Covering Use of Efzofitimod with Pirfenidone for Lung Inflammation or Fibrosis
Patent highlights potential benefit of efzofitimod as a combination therapy for IPF standard of care….
Apexigen Announces New Phase 2 Data Evaluating Sotigalimab, its CD40 Agonist Antibody, at ASCO Gastrointestinal Cancers Symposium 2023
-Results demonstrate sotigalimab’s ability to turn immunologically “cold” tumors “hot” to increase anti-tumor immune responses…
FDA Accepts Intercept’s New Drug Application for OCA for the Treatment of Pre-Cirrhotic Liver Fibrosis Due to NASH
NDA is supported by robust NASH clinical development program, including two positive interim analyses from…